Navigation Links
BCM-95 Demonstrates Superior Anti-Inflammatory Effects
Date:9/16/2010

GREEN BAY, Wis., Sept. 16 /PRNewswire/ -- Top researchers at the Gastrointestinal Cancer Research Lab at Baylor University Medical Center in Dallas are exploring the clinical applications of BCM-95®, a new patented extract of curcumin with unprecedented potency, and bioavailability.

Previous studies have shown that BCM-95 curcumin was 7-10 times more bioavailable than other forms of curcumin, and had a retention time in the bloodstream between 8 to 12 hours.(1) At all points in the study, BCM-95 curcumin levels were higher than any other form of curcumin tested. This superior absorption and retention is attained by a patented process that involves homogenization and micronization with turmeric essential oil which is then bound to natural plant phospholipids.

"We have the most fascinating and convincing scientific laboratory evidence from thousands of  studies finding that curcumin has potent anti-inflammatory properties," said Ajay Goel, Ph.D., Investigator at the Gastrointestinal Cancer Research Lab at Baylor University. "Abundant data point to the pain-relieving and anti-inflammatory efficacy of curcumin – and these benefits are essentially drawn from its ability to suppress and inhibit the activities of two major pro-inflammatory targets within our cells: NF-kB and COX-2." Dr. Goel's  group was the first to demonstrate that curcumin acts as a specific COX-2 inhibitor, and hence, plays an important role in not only alleviating everyday pain, but has the potential to prevent many chronic diseases that manifest themselves in the background of increased inflammation.

While curcumin holds huge promise as an anti-inflammatory, pain relieving substance, in the human body curcumin is poorly absorbed.  "However, BCM-95 amplifies and potentiates its effectiveness," Dr. Goel explained. "Not only is BCM-95 curcumin absorbed up to 10 times better than conventional curcumin, it also is retained in the body longer. Currently, we have several scientific studies underway in our laboratory on BCM-95, and we are extremely encouraged by the new promising discoveries we are making with this miracle herb."

According to Dr. Goel, inflammation is a factor in 80-90% of all disease. Curcumin demonstrates superior antioxidant and anti-inflammatory effects, and provides liver and heart-protective benefits as well. It is a potent anti-bacterial, anti-fungal, anti-viral, anti-allergenic, and has anti-tumor and anti-cancer properties.

EuroPharma, Inc. is the exclusive distributor of BCM-95® in the U.S. through both the health food store and professional distribution channels. EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. At EuroPharma, Our Passion is Your Health®. For more information on EuroPharma, visit www.EuroPharmaUSA.com.

(1) Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyala S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax) a novel bioenhanced preparation of curcumin. Ind J Pharm Sci. 2008. 2008;70(4):445-450.


'/>"/>
SOURCE EuroPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EuroPharma Exclusive Distributor of BCM-95 and BosPure
2. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):